# A Polypill for Secondary Prevention of Ischemic Heart Disease

Study · id `cardio:ct-nct03541109` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03541109](<https://clinicaltrials.gov/study/NCT03541109>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03541109

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1200 participants.

## Technical summary

Registry record NCT03541109. Randomized; no masking; primary purpose treatment. Start 2019-05-20 (actual); primary completion 2023-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1200 participants (planned count; ClinicalTrials.gov record NCT03541109, source copy `cardio:ctgov-nct03541109-2020-10-14`, retrieved 2026-10-26)
- Started: 2019-05-20 (actual) (ClinicalTrials.gov record NCT03541109, source copy `cardio:ctgov-nct03541109-2020-10-14`, retrieved 2026-10-26)
- Primary completion: 2023-08 (anticipated) (ClinicalTrials.gov record NCT03541109, source copy `cardio:ctgov-nct03541109-2020-10-14`, retrieved 2026-10-26)
- Completion: 2024-08 (anticipated) (ClinicalTrials.gov record NCT03541109, source copy `cardio:ctgov-nct03541109-2020-10-14`, retrieved 2026-10-26)
- Countries: Iran (ClinicalTrials.gov record NCT03541109, source copy `cardio:ctgov-nct03541109-2020-10-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03541109-2020-10-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Polypill for Secondary Prevention of Ischemic Heart Disease
- Condition: Acute Myocardial Infarction
- Condition: ST Elevation Myocardial Infarction
- Condition: Non-ST Elevation Myocardial Infarction
- Intervention (Drug): Polypill
- Lead sponsor: Isfahan University of Medical Sciences
- Lead sponsor class: OTHER
- Collaborator: Tehran University of Medical Sciences
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as a collaborator: Tehran University of Medical Sciences (`cardio:org-tehran-university-of-medical-sciences`)

## Provenance

Content hash: b947f02b4b0d8bd5e5231eeae5867b756e66b8387ebb63c42856f893adddfc78
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
